Publications by authors named "Castilho V Q Dos Santos"

Background: The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is unclear.

Methods: We conducted a double-blind, randomized, placebo-controlled, adaptive platform trial involving symptomatic SARS-CoV-2-positive adults recruited from 12 public health clinics in Brazil. Patients who had had symptoms of Covid-19 for up to 7 days and had at least one risk factor for disease progression were randomly assigned to receive ivermectin (400 μg per kilogram of body weight) once daily for 3 days or placebo.

View Article and Find Full Text PDF
Article Synopsis
  • Recent research suggests fluvoxamine may help prevent hospitalizations in patients with COVID-19, as studied in the TOGETHER trial involving symptomatic Brazilian adults.
  • In this randomized, placebo-controlled trial, participants were assigned to receive either fluvoxamine (100 mg twice daily for 10 days) or a placebo, while treatment allocation was kept blind for all involved.
  • Out of 9,803 screened patients, the trial included 741 on fluvoxamine and 756 on placebo, with findings indicating superior outcomes for fluvoxamine in reducing COVID-19 related hospitalizations.
View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_session12cloa512ugjehfip17ec5gttbpi514u): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once